Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations--the ECTIM Study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (APOE) is a major protein in lipid metabolism existing in three common isoforms: APOE2, -3 and -4. The varepsilon4 allele of the APOE gene ( APOE ) coding for the APOE4 isoform is associated with an increased risk of myocardial infarction (MI) and of Alzheimer's disease (AD). Recently, several polymorphisms in the APOE regulatory region have been reported. Some of these have been associated with AD and modified APOE allelic mRNA expression in AD brains. Here, we have investigated whether three of these promoter polymorphisms (-491AT, -427CT and -219GT) can also modify cardiovascular risk. The hypothesis was tested in a large multicentre case-control study of MI, the ECTIM Study, on 567 cases and 678 controls. Among the three APOE promoter polymorphisms tested, only the-219T allele was associated with a significantly increased risk of MI (OR = 1.29, 95% CI: 1.09-1.52, P < 0.003) and the effect was shown to be independent of the presence of the other mutations, including the APOE epsilon2/epsilon3/epsilon4 polymorphism. Moreover, the-219T allele greatly decreased the APOE plasma concentrations in a dose-dependent manner ( P < 0.008). These data indicate that the-219GT polymorphism of the APOE regulatory region emerges as a new genetic susceptibility risk factor for MI and constitutes another common risk factor for both neurodegenerative and cardiovascular diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363 · cited 1×
“In Alzheimer’s disease (AD), theAPOE 4 allele is also strongly associated with an increased risk of developing the disease but, as in CHD, individuals bearing APOE 4 do not necessarily develop dementia (6).”
BackgroundBellosta, S., Mahley, R. W., Sanan, D. A., Murata, J., Newland, D. L., Taylor, J. M., & Pitas, R. E. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118271 · Cited by 284
Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene
Artiga, M. J., Bullido, M. J., Sastre, I., Recuero, M., Garcı́a, M. A., Aldudo, J., Vázquez, J., & Valdivieso, F. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01543-3 · Cited by 229 · cited 2×
“However, we were able to associate the –21 allele with lower APOE plasma concentrations, th observation being in agreement with the previously report lower expression of APOEassociated with the presence of th –219T allele in HepG2 transfected cells (10).”
BackgroundResult
Cited by
Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease
Song, Y., Stampfer, M. J., & Liu, S. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-2-200407200-00013 · Cited by 528
Fullerton, S. M., Clark, A. G., Weiss, K. M., Nickerson, D. A., Taylor, S. L., Stengård, J. H., Salomaa, V., Vartiainen, E., Perola, M., Boerwinkle, E., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/303070 · Cited by 432
Deciphering the Genetic Basis of Alzheimer's Disease
Selkoe, D. J., & Podlisny, M. B. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.022502.103022 · Cited by 294
Morgan, T. M., Krumholz, H. M., Lifton, R. P., & Spertus, J. A. (2007) · JAMA · doi:10.1001/jama.297.14.1551 · Cited by 270
Laws, S. M., Hone, E., Gandy, S., & Martins, R. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01615.x · Cited by 223
“The ) 219T/G promoter polymorphism has also been associated with altered levels of plasma apoE (Lambert et al. 2000).”
BackgroundSequence Diversity and Large-Scale Typing of SNPs in the Human Apolipoprotein E Gene
Nickerson, D. A., Taylor, S. L., Fullerton, S. M., Weiss, K. M., Clark, A. G., Stengård, J. H., Salomaa, V., Boerwinkle, E., & Sing, C. F. (2000) · Genome Research · doi:10.1101/gr.146900 · Cited by 184
“) A number of recent studies have focused attention on SNPs in the 5 flanking region of APOE that could alter gene expression and be involved in the phenotypic associations with Alzheimer’s disease and CVD risk (Mui et al. 1996; Artiga et al. 1998a,b; Bullido et al. 1998; Lambert et al. 1998a,b; Lambert et al. 2000).”
BackgroundMolecular Genetics of Late‐Onset Alzheimer's Disease
Kamboh, M. I. (2004) · Annals of Human Genetics · doi:10.1046/j.1529-8817.2004.00110.x · Cited by 170
“The TFCP2 3′UTR polymorphism may be functional, as it affects the binding of a transcription factor (Lambert et al. 2000).”
BackgroundHeritabilities of Apolipoprotein and Lipid Levels in Three Countries
Beekman, M., Heijmans, B. T., Martin, N. G., Pedersen, N. L., Whitfield, J. B., DeFaire, U., van Baal, G. C. M., Snieder, H., Vogler, G. P., Slagboom, P. E., et al. (2002) · Twin Research · doi:10.1375/twin.5.2.87 · Cited by 133
“Additionally, the T allele of the –219GT APOE promoter polymorphism is independently associated with lower levels of apolipoprotein E (Lambert et al., 2000).”
Simon, R., Girod, M., Fonbonne, C., Salvador, A., Clément, Y., Lantéri, P., Amouyel, P., Lambert, J. C., & Lemoine, J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018861 · Cited by 92
Self-citationAllelic expression of APOE in human brain: Effects of epsilon status and promoter haplotypes
Bray, N. J., Jehu, L., Moskvina, V., Buxbaum, J. D., Dracheva, S., Haroutunian, V., Williams, J., Buckland, P. R., Owen, M. J., & O'Donovan, M. C. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh299 · Cited by 45
“The 2219T allele has previously been associated with reduced transcriptional activity in vitro (17) and with reduced plasma ApoE in vivo (22).”
BackgroundRadwan, Z. H., Wang, X., Waqar, F., Pirim, D., Niemsiri, V., Hokanson, J. E., Hamman, R. F., Bunker, C. H., Barmada, M. M., Demirci, F. Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114618 · Cited by 27
“APOE832/ rs405509 located in the putative promoter region has previously been shown to be associated with LDL-related traits (LDL-C, TC, and ApoB) [16–17, 45], APOE gene expression [46], myocardial infarction risk [47], and premature CHD [48].”
BackgroundIs the distinction between Alzheimer's disease and vascular dementia possible and relevant?
Ravona-Springer, R., Davidson, M., & Noy, S. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/rravonaspringer · Cited by 18
Combined association and linkage analysis applied to the APOE locus
Beekman, M., Posthuma, D., Heijmans, B. T., Lakenberg, N., Suchiman, H. E. D., Snieder, H., de Knijff, P., Frants, R. R., van Ommen, G. J. B., Kluft, C., et al. (2004) · Genetic Epidemiology · doi:10.1002/gepi.10318 · Cited by 16
“Previously, the 219G/T polymorphism was associated with apoE plasma levels [Lambert et al., 2000; Stengard et al., 2002].”
Background
Metadata
- Authors
- Lambert, J.-C.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-01-01
- Volume
- 9
- Issue
- 1
- Pages
- 57-61
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2141583641
- Cited by
- 147
- References
- 3
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.